Hims & Hers Health shares dip amid rising selling pressure

Traders Union
All News
Financial News
Hims & hers slides 5.54% today

Highlights

Hims & Hers Health cut adjusted Q1 2026 earnings from a prior profit to an $0.18 loss per share, driven by softer online revenue per subscriber.
Despite near-term headwinds, full-year revenue guidance was raised to $2.8 billion–$3 billion, though the stock faced persistent selling pressure.
Technical indicators show mixed momentum with overbought signals and a projected trading range of $26.76–$30.79, suggesting risk of further downside if support fails.

Revenue drop and widened loss temper optimism from raised annual guidance

Hims & Hers Health Inc. reported a 5.9% year-over-year decrease in monthly online revenue per average subscriber to $80 for the first quarter of 2026, attributed to changes in shipping cadence for certain products. The company disclosed an adjusted loss per share of 18 cents in Q1 2026, compared to a 20 cent profit a year earlier. The company also raised its full-year revenue guidance to a range between $2.8 billion and $3 billion, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees several red flags for Hims & Hers Health after the latest session. The daily drop of 5.54% contradicts underlying bullish momentum and raises doubt about the stock's resilience. He points to falling online revenue per subscriber, a swing from a small profit to an adjusted loss, and persistent pressure under the MA-200 as key weaknesses. The technical overbought signals and weak trend strength further undermine the case for a near-term rebound. "Short-term rallies look fragile — I see increased risk of further downside unless serious buying returns above $28," warns Kharitonov.

Viktoras Karapetjanc, expert at Traders Union, believes the bullish structure remains intact for Hims & Hers Health despite short-term volatility. He notes that raised full-year revenue guidance and positive medium-term technicals outweigh the near-term decline and one-off weakness in subscriber revenues. Karapetjanc views buyer dominance on momentum signals as a sign of underlying market confidence. "Even with today’s pullback, I expect further growth — the market offers multiple setups for continued upside as macro and company trends support the case," he states.

Jainam Mehta, market strategist, sees a short-term divergence in momentum for Hims & Hers Health. The asset trades above key moving averages but faces strong longer-term resistance below the MA-200. Mehta suggests that the overbought signals could trigger tactical pullbacks, yet a clean break above $28 may set up a potential breakout. "Current sentiment may be stretched — I’d watch for contrarian entries if price action stabilizes above $28 or drops closer to support," says Mehta.

Short-term bullish signals meet overbought risks and weak trend strength

Hims & Hers Health is trading above both the MA-20 ($25.76) and MA-50 ($25.49), signaling a strong short- to medium-term bullish trend, but well below the MA-200 ($33.66), which indicates longer-term resistance remains. The nearest notable support is the Ichimoku Kijun at $25.96, with dynamic resistance expected near the MA-50 and the round level at $28. Momentum signals are mixed: the MACD shows a positive bias, but the Average Directional Index (ADX) indicates weak overall trend strength. The Relative Strength Index (RSI) stays in neutral-to-bullish territory, yet the Stochastic RSI and Commodity Channel Index (CCI) signal overbought conditions. Bull/Bear Power (BBP) is firmly positive, pointing to buyer dominance, but it also signals overbought, underscoring the risk of short-term pullback. The price is down $1.60 or 5.54% today, following a downside opening gap of roughly $0.14. The stock is near the daily low, intraday volatility stands at 2.61%, and the session currently shows selling pressure with weak attempts at a rebound. This decline contradicts some momentum signals and highlights a short-term divergence between daily price action and underlying bullish momentum indicators.

Earlier, analysts noted that Hims & Hers Health was exhibiting short- to medium-term bullish momentum, but with overbought conditions and the risk of volatility-driven pullbacks. The current downturn and mixed indicator signals highlight heightened downside risk, making $26.76 an important support level for traders to monitor in the near term.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.